UBS Group began coverage on shares of ARM (NASDAQ:ARM – Free Report) in a report published on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $160.00 price target on the stock.
A number of other research firms also recently commented on ARM. TD Cowen increased their price objective on shares of ARM from $150.00 to $165.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Susquehanna boosted their target price on ARM from $115.00 to $118.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Raymond James began coverage on shares of ARM in a research note on Friday, September 13th. They issued an “outperform” rating and a $160.00 price objective for the company. Hsbc Global Res upgraded ARM to a “moderate sell” rating in a research note on Monday, July 29th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ARM in a research report on Thursday, November 7th. Two analysts have rated the stock with a sell rating, six have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $150.32.
Get Our Latest Research Report on ARM
ARM Stock Performance
ARM (NASDAQ:ARM – Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.04. ARM had a net margin of 18.13% and a return on equity of 13.69%. The business had revenue of $844.00 million for the quarter, compared to the consensus estimate of $810.03 million. During the same period last year, the firm posted $0.36 earnings per share. The company’s revenue was up 4.7% compared to the same quarter last year. Equities research analysts forecast that ARM will post 0.79 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Franklin Resources Inc. boosted its holdings in shares of ARM by 21.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,281,484 shares of the company’s stock valued at $183,265,000 after purchasing an additional 228,467 shares during the last quarter. International Assets Investment Management LLC lifted its holdings in ARM by 14,351.1% in the 3rd quarter. International Assets Investment Management LLC now owns 812,297 shares of the company’s stock worth $1,161,670,000 after buying an additional 806,676 shares in the last quarter. Sei Investments Co. grew its stake in shares of ARM by 551.6% during the second quarter. Sei Investments Co. now owns 579,330 shares of the company’s stock valued at $94,790,000 after acquiring an additional 490,415 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of ARM by 186.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 359,105 shares of the company’s stock valued at $52,279,000 after purchasing an additional 233,909 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of ARM by 5.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 290,947 shares of the company’s stock valued at $36,366,000 after buying an additional 14,584 shares during the last quarter. 7.53% of the stock is currently owned by institutional investors and hedge funds.
ARM Company Profile
Arm Holdings plc architects, develops, and licenses central processing unit products and related technologies for semiconductor companies and original equipment manufacturers rely on to develop products. It offers microprocessors, systems intellectual property (IPs), graphics processing units, physical IP and associated systems IPs, software, tools, and other related services.
Further Reading
- Five stocks we like better than ARM
- Ride Out The Recession With These Dividend Kings
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How to Evaluate a Stock Before Buying
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for ARM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARM and related companies with MarketBeat.com's FREE daily email newsletter.